Plus Therapeutics (PSTV) AI Stock Analysis

• Market Cap: $67.35M
• Dividend Yield: N/A
• Average Volume (3M): 7.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -8.16%
• EPS Growth: 22.44%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 137,429,060
• 10 Day Avg. Volume: 4,355,479
• 30 Day Avg. Volume: 7,856,676
• PEG Ratio: 0.01
• Price to Book (P/B): -0.85
• Price to Sales (P/S): 1.31
• P/FCF Ratio: -0.71
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 10.82
• Enterprise Value/Gross Profit: 12.17
• Enterprise Value/Ebitda: -3.52
• 1Y Price Target: $7.75
• Price Target Upside: 1236.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.18
• Revenue Forecast (FY): $4.94M

• Rating: 40 Underperform
• Price Target: $0.50 ▼(-13.79% Downside)

Plus Therapeutics faces significant financial challenges with negative equity and cash flow difficulties, heavily impacting its overall score. Technical indicators suggest a bearish trend, further weighing on the stock's outlook. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Overall, the stock presents high risks with limited upside potential.

Positive Factors

Innovative Product Development

The focus on Rhenium-186 NanoLiposome for targeted cancer treatment positions Plus Therapeutics as an innovator in the biopharmaceutical sector, potentially leading to significant advancements in cancer therapy and long-term growth opportunities.

Strategic Subsidiary Launch

The launch of CNSide Diagnostic's test enhances Plus Therapeutics' market presence in CNS cancer diagnosis, addressing unmet needs and potentially driving revenue growth through innovative diagnostic solutions.

Strategic Partnerships

The national coverage agreement with UnitedHealthcare could enhance market access and reimbursement for Plus Therapeutics' products, supporting long-term revenue stability and market penetration.

Negative Factors

Negative Equity

Negative equity indicates financial distress, limiting Plus Therapeutics' ability to raise capital and invest in growth, posing long-term risks to its financial health and operational sustainability.

Consistent Losses

Ongoing losses and lack of revenue generation highlight operational inefficiencies and financial instability, which could hinder Plus Therapeutics' ability to sustain its business model and achieve profitability.

Cash Flow Challenges

Negative cash flow from operations suggests inefficiencies and potential liquidity issues, impacting Plus Therapeutics' capacity to fund its R&D activities and strategic initiatives over the long term.

Plus Therapeutics Business Overview & Revenue Model

Company Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

How the Company Makes Money

Plus Therapeutics generates revenue primarily through the advancement of its product candidates into clinical trials, which may attract funding from partnerships, grants, and collaborations with pharmaceutical companies or research institutions. The company may also benefit from government grants and incentives for developing treatments that address significant health challenges. Additionally, once products receive regulatory approval, PSTV can generate revenue through product sales, licensing agreements, and potential royalties from partners. Strategic partnerships with larger pharmaceutical companies could enhance their financial stability by providing upfront payments and milestone payments tied to the successful development of their therapies.

Plus Therapeutics Financial Statement Overview

Summary

Plus Therapeutics is in a challenging financial position with consistent losses, negative equity, and cash flow difficulties. The financial health of the company suggests significant risks and a need for strategic restructuring to improve its financial trajectory.

Income Statement

Plus Therapeutics has faced significant challenges with no revenue reported in the most recent year and consistent net losses over time. The company experienced severe negative EBIT and EBITDA margins. Revenue growth has been volatile and negative, reflecting instability in income generation.

Balance Sheet

The company's balance sheet reveals negative stockholders' equity, indicating potential financial distress. The debt-to-equity ratio cannot be computed meaningfully due to negative equity. Additionally, Plus Therapeutics has a high level of debt relative to its assets, posing potential solvency risks.

Cash Flow

Cash flow analysis shows persistent negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative, suggesting inefficiencies. Despite some financing inflows, the company struggles with cash flow sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.26M	5.82M	4.91M	224.00K	0.00	303.00K
Gross Profit	4.67M	4.97M	-4.78M	-488.00K	-66.00K	-2.40M
EBITDA	-16.14M	-8.40M	-12.69M	-18.85M	-12.05M	-8.44M
Net Income	-20.58M	-12.98M	-13.32M	-20.27M	-13.40M	-8.24M
Balance Sheet
Total Assets	18.67M	6.63M	11.39M	23.87M	21.98M	12.11M
Cash, Cash Equivalents and Short-Term Investments	13.29M	3.61M	8.55M	18.12M	18.40M	8.35M
Total Debt	21.00K	3.37M	4.18M	5.75M	6.99M	7.00M
Total Liabilities	13.62M	15.58M	12.74M	17.42M	11.14M	9.07M
Stockholders Equity	5.05M	-8.95M	-1.35M	6.45M	10.84M	3.03M
Cash Flow
Free Cash Flow	-15.78M	-10.70M	-13.01M	-13.73M	-10.42M	-8.93M
Operating Cash Flow	-15.73M	-10.55M	-12.85M	-12.97M	-10.28M	-8.43M
Investing Cash Flow	287.00K	-4.11M	-160.00K	-759.00K	-82.00K	-493.00K
Financing Cash Flow	27.51M	6.19M	3.44M	13.45M	20.42M	-319.00K

Plus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSTV, the sentiment is Negative. The current price of 0.58 is above the 20-day moving average (MA) of 0.54, above the 50-day MA of 0.58, and below the 200-day MA of 0.63, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.10 is Neutral, neither overbought nor oversold. The STOCH value of 29.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSTV.

Plus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KPTI	49 Neutral	$101.96M	-0.41	―	―	-3.98%	-29.94%
SNTI	47 Neutral	$46.27M	-0.53	-394.62%	―	―	78.60%
BRNS	42 Neutral	$31.41M	―	-62.30%	―	-100.00%	-26.30%
PSTV	40 Underperform	$67.35M	―	―	―	-8.16%	22.44%
TVRD	37 Underperform	$41.17M	-0.25	-97.61%	―	-53.67%	86.75%
ACRV	36 Underperform	$75.10M	―	-50.23%	―	―	21.17%

Plus Therapeutics Corporate Events

Plus Therapeutics Gains Nasdaq Extension for Compliance

On November 17, 2025, Plus Therapeutics announced it received an additional 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, extending the deadline to May 11, 2026. The extension allows Plus Therapeutics to continue trading on the Nasdaq Capital Market under the symbol ‘PSTV’ without immediate risk of delisting. The company is considering options, including a reverse stock split, to meet compliance, but there is no assurance of success. Failure to comply could result in delisting, which can be appealed.

The most recent analyst rating on (PSTV) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Plus Therapeutics Signs Lease Agreement in Houston

On October 16, 2025, Plus Therapeutics, Inc. entered into a lease agreement with LG 1 Property Owner LP for approximately 11,370 rentable square feet of space at 6420 Levit Green Boulevard, Houston, Texas. The lease, commencing on or about November 1, 2026, includes a monthly base rent of $58,745, with an annual increase of approximately 3%, and has an initial term of 120 months.

The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Plus Therapeutics Secures Nasdaq Compliance Extension

On August 22, 2025, Plus Therapeutics, Inc. received confirmation from Nasdaq that it complies with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities standard and the alternative stockholders’ equity threshold. This compliance allows the company to extend its grace period to meet the $1.00 bid price rule until November 12, 2025. However, the company is subject to a one-year monitoring period regarding the Equity Standard. If it fails to maintain compliance within this period, Nasdaq will issue a delist determination letter, though the company can request a hearing to potentially stay further actions.

The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.